Search results
Results From The WOW.Com Content Network
Mr. Justice Aftab Alam [1] Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the ...
Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2] Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and ...
Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
August 5, 2024 at 4:42 PM. By Blake Brittain. (Reuters) - Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her ...
Price to pay What could happen if the charges against Novartis are found to be true? At minimum, the company would probably pay steep penalties. As part of its 2010 agreement, Novartis paid $422 ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
The Ritalin class-action lawsuits were a series of federal lawsuits in 2000, filed in five separate US states. All five lawsuits were dismissed by the end of 2002. The lawsuits alleged that the makers of methylphenidate (brand name Ritalin) and the American Psychiatric Association had conspired to invent and promote the disorder ADHD to create a highly profitable market for the drug.
Novartis AG said on Tuesday a U.S. court of appeals upheld the validity of a dosage regimen patent for its multiple sclerosis treatment Gilenya, allowing a permanent injunction against Chinese ...